1 Department of Medicine and Surgery, Milan Center for Neuroscience, University of Milano-Bicocca, Milan, Italy.
2 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419827745. doi: 10.1177/2058738419827745.
The objective of this study was to evaluate the effects of lozenges-containing Lactobacillus reuteri as an adjuvant treatment of peri-implant mucositis and to detect the level of L. reuteri colonization in the peri-implant tissues of treated patients. A total of 10 patients were selected. Subjects with at least one implant affected by peri-implant mucositis, with gingival index (GI) of ⩾2 in each quadrant, evaluated at the buccal aspect of all teeth. Patients included in the study were partially edentulous and had implants with mucositis or peri-implantitis. Implants with radiographic bone loss of ⩾5 mm and/or ⩾50% of the implant length were excluded, and only one implant per patient was included. Each patient received L. reuteri-containing lozenges. Microbiological sampling was performed at baseline and on day 28 and analysed by polymerase chain reaction (PCR). Our results indicate that the use of the probiotic did not influence the peri-implant microbiota in a statistically significant way, although there was a reduction in the number of periodontal and peri-implant species. The lack of statistically significant microbiological changes could be explained either by the small sample population or by the short evaluation period. Therefore, the poor colonization of L. reuteri in the peri-implant pockets can be explained by the different anatomical and histological characteristics of the interface of the dental-gingival unit with respect to the periodontal sulcus. The administration of a daily lozenge of L. reuteri for 4 weeks had a limited effect on the microbiological analysis. Probiotics provide an alternative therapeutic approach to consider in the prevention and treatment of peri-implant diseases, but further long-term prospective studies with standardized variables are needed.
本研究旨在评估含嗜酸乳杆菌含片作为辅助治疗种植体周围黏膜炎的效果，并检测治疗患者种植体周围组织中嗜酸乳杆菌的定植水平。共选择了 10 名患者。在每个象限的颊面，选择至少有一个种植体受种植体周围黏膜炎影响，牙龈指数（GI） ⩾2 的患者。纳入研究的患者为部分缺牙，且有黏膜炎或种植体周围炎的种植体。排除有 ⩾5 mm 放射状骨丧失和/或 ⩾50%种植体长的种植体，每位患者仅纳入一个种植体。每位患者均接受含嗜酸乳杆菌的含片。在基线和第 28 天进行微生物取样，并通过聚合酶链反应（PCR）进行分析。我们的结果表明，益生菌的使用并没有以统计学显著的方式影响种植体周围微生物群，尽管牙周和种植体的种类数量有所减少。微生物学变化没有统计学显著的原因可能是样本人群较小或评估期较短。因此，嗜酸乳杆菌在种植体周围袋内定植不良，可以用牙-龈单位的界面的解剖学和组织学特征与牙周袋的不同来解释。4 周每日含嗜酸乳杆菌含片的使用对微生物分析的影响有限。益生菌为预防和治疗种植体周围疾病提供了一种可供考虑的替代治疗方法，但需要进一步进行长期前瞻性研究，标准化变量。
